Gossamer lays off 25% of employees, cuts all programs except PAH drug

Amber Tong

As Gossamer Bio goes all in on its lead drug for pulmonary arterial hypertension (PAH), it’s cutting off all other clinical and preclinical programs …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gossamer lays off 25% of employees, cuts all programs except PAH drug

Amber Tong

Sign up to read this article for free.

Pfizer looking to sell hospital drugs unit — reports

AstraZeneca CEO reaffirms commitment to China following executive's detention

'Expertise is a real thing': FDA commissioner warns of political risk to agency

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Gos­samer lays off 25% of em­ploy­ees, cuts all pro­grams ex­cept PAH drug

Amber Tong

Sign up to read this article for free.

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Gossamer lays off 25% of employees, cuts all programs except PAH drug

Pfizer looking to sell hospital drugs unit — reports

AstraZeneca CEO reaffirms commitment to China following executive's detention

'Expertise is a real thing': FDA commissioner warns of political risk to agency

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?